8.20
-0.61%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Promimic
Its shares trade on Nasdaq Stockholm under the ticker PRO.ST. It has been listed since 29 April 2022. In the fiscal year to 31 December 2025, it reported revenue of SEK 44.4m and a net loss of SEK 8.8m. At that date it held total assets of SEK 75.7m and shareholders' equity of SEK 59.1m.
Promimic AB operates as a holding company that develops and markets implant surface modifications and synthetic bone based on a patented method for production of nano sized hydroxyapatite. The company is headquartered in Moelndal, Vastra Gotalands. The company went IPO on 2022-04-29. The firm manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The firm operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 29 Apr 2022
- Website
- promimic.com ↗
Leadership
Pay as last reported
- Mr. Tommy KarlssonIndependent Chairman of the BoardSEK 350,000
- Mr. Magnus LarssonChief Executive Officer, Managing DirectorSEK 1.9m
- Mr. Per KjellinCo-Founder, Chief Technology Officer
- Mr. Martin AnderssonBoard member, Co-Founder, since 2021SEK 100,000
- Ms. Heidi BaderChief Financial Officer
- Mr. Ulf BrogrenChief Compliance OfficerSEK 1.2m
- Mr. Chris WhitfieldVD Promimic Inc
- Mr. Johan DighedBoard member
- Mr. Pehr AbrahamssonIndependent Board memberSEK 150,000
- Ms. Helena BrisbyIndependent Board memberSEK 150,000
- Mr. Johan HolmstromIndependent Board Member
- Ms. Pia RenaudinIndependent Board Member
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Promimic AB's patented nano hydroxyapatite method enhances bone healing in dental and orthopedic implants.
- The company's biomaterials are used in spine, total joint, and sports medicine implant markets globally.
- Promimic AB's products are marketed in the United States, Europe, and South America for osseointegration.
Weaknesses
- Promimic AB's operations are limited to the Life Sciences Tools & Services sector within Health Care.
- The company's focus on biomaterials for implant surfaces restricts market diversification.
- Promimic AB's product applications are currently limited to dental, spine, and joint implant markets.
Opportunities
- Promimic AB can expand its biomaterials into new markets like sports medicine and extremities implants.
- The growing demand for improved osseointegration in dental and orthopedic implants presents opportunities.
- Promimic AB's presence in the United States, Europe, and South America supports global market growth.
Threats
- Promimic AB faces competition from established players in the Health Care sector.
- The company's reliance on a single patented technology could pose risks if challenged.
- Regulatory changes in the Life Sciences Tools & Services industry may impact operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.